Evaluation of 2 Synthetic Nitrile Male Condoms Compared to a Standard Latex Male Condom
Launched by KAREX INDUSTRIES SDN. BHD. · Jun 12, 2023
Trial Information
Current as of July 06, 2025
Completed
Keywords
ClinConnect Summary
A sequential randomised 3-period cross-over trial comparing five uses of two synthetic nitrile male condoms of different sizes with a control latex male condom. Each couple will be asked to use five synthetic nitrile condoms (53 mm width), five synthetic nitrile condoms (56 mm width) and five latex male condoms (53 mm width) in a randomised order. Couples will complete a Condom Use Report after each condom use. Function, safety, and acceptability will be assessed at each of three follow-up visits conducted after using each set of five condoms. The trial will enrol 300 couples, anticipating ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Be between the ages of 18 and 45 years (inclusive);
- • 2. Be literate (able to read a newspaper or letter easily);
- • 3. Have been in an exclusive (monogamous) sexual relationship with partner for at least 3 months; and intend to continue to be an exclusive (monogamous) sexual relationship with their spouse or partner while participating in this research study;
- • 4. Be sexually active (defined as having at least one vaginal coital act per week);
- • 5. Willing to give informed consent;
- • 6. Willing to complete the male condom coital use reports;
- • 7. Willing to use the study condoms as directed;
- • 8. Agree to use only the study lubricant provided;
- • 9. Agree to only use the study condoms sequentially during time of participation
- • 10. Willing to adhere to the follow-up schedule and all study procedures;
- • 11. Willing to provide research study staff with an address, phone number or other locator information while participating in the study;
- • 12. Willing to participate in the study for the duration of 15 condom uses (approximately 3-5 months);
- • 13. Willing to provide photo identification and/or have fingerprint scan to exclude co-enrolment in other research projects;
- • 14. Female partner using hormonal or other non-barrier contraception (e.g. OCs, injectable, implant, IUD, or have had a tubal sterilization) or male partner vasectomised;
- • 15. Agree to return any unopened condoms;
- • 16. Male partner willing to ejaculate during vaginal intercourse;
- • 17. Male partner willing to hold on to the condom ring when withdrawing the erect penis after sexual intercourse;
- • 18. Agree to not bring study condoms in contact with genital or oral piercing jewelry
- • 19. EAH: Both partners have valid personal email and operable mobile phones;
- Exclusion Criteria:
- • 1. Female partner is pregnant or desires to become pregnant during the time of the research study;
- • 2. Either partner is known to be HIV positive (based on self report \[EAH\] or documented HIV-negative test result within past two months \[MRU\]);
- • 3. Self-reported history of recurrent sexually transmitted infection (e.g. gonorrhea, syphilis, Chlamydia);
- • 4. Male partner has known erectile or ejaculatory dysfunction;
- • 5. Either partner has genital piercing jewelry, uses genital beading or uses sex toys, drugs, medications or non-study devices that can affect sexual performance;
- • 6. Either partner has known sensitivities or allergies to latex, synthetic nitrile, vaginal/sexual lubricants or lubricants used on condoms;
- • 7. Either partner reports symptoms of STI (EAH) or has observable evidence of STI as determined through syndromic diagnosis and vaginal/penile examination (MRU);
- • 8. Either partner is currently participating in another condom study;
- • 9. Either partner is a past or current employee of Essential Access Health, University of the Witwatersrand, or Karex;
- • 10. Either partner is a sex worker.
About Karex Industries Sdn. Bhd.
Karex Industries Sdn. Bhd. is a leading global manufacturer specializing in the production of high-quality latex and synthetic condoms, renowned for its commitment to innovation and safety in sexual health products. With a robust research and development framework, Karex actively engages in clinical trials to advance public health outcomes and ensure the efficacy and reliability of its products. The company is dedicated to promoting safe practices and improving access to sexual health solutions worldwide, aligning its operations with stringent quality standards and regulatory compliance. Through its initiatives, Karex aims to contribute significantly to the global fight against sexually transmitted infections and unintended pregnancies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Berkeley, California, United States
Durban, Kwa Zulu Natal, South Africa
Patients applied
Trial Officials
Mags Beksinska, PhD
Principal Investigator
MatCH Research Unit (MRU)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported